A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Inclusion Criteria: * Part 1: Healthy male volunteers 18 to 45 years of age * Part 1: Left ventricular ejection fraction (LVEF) at least 55 percent (%) * Part 1: Body mass index (BMI) 18 to 32 kilograms per meter-squared (kg/m\^2) * Part 1: Normal, intact skin without tattoos or lesions in the injection area * Part 2: Females at least 18 years of age * Part 2: Eastern Cooperative Oncology Group (ECOG) performance status of 0 * Part 2: Previously treated, non-metastatic carcinoma of the breast * Part 2: Baseline LVEF at least 55% * Part 2: Negative pregnancy test and use of adequate contraceptive measures among women of childbearing potential Exclusion Criteria: * Part 1: Positive urine test for drugs of abuse * Part 1: History of exposure or active viral infection of Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) * Part 1: Cardiac disease including hypertension or hypotension * Part 1: Lower extremity edema * Part 1: Any clinically relevant history of systemic disease * Part 1: History of breast cancer * Part 1: Chronic corticosteroid use * Part 1: Receipt of IV antibiotics within 7 days prior to enrollment * Part 2: Concurrent malignancy requiring therapy that may interfere with pharmacokinetic investigations, or history of other malignancy within 5 years prior to Screening * Part 2: Significant cumulative exposure to anthracyclines * Part 2: Serious cardiac disease including uncontrolled hypertension * Part 2: Poor hematologic, renal, or hepatic function * Part 2: Pregnant or lactating women * Part 2: History of exposure or active viral infection of Hepatitis B, hepatitis C, or HIV * Part 2: Chronic corticosteroid use * Part 2: Receipt of IV antibiotics within 7 days prior to enrollment